RxDoctor Payments Data

John Berry, MD

Hematology & Oncology · Berwyn, ILNPI 1194702795

Payments from drug & device makers

$687,312in general payments, 2019–2025

Across 612 payments — averaging $1123.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Exelixis Inc.$210K
  • AstraZeneca$133K
  • Daiichi Sankyo Inc.$117K
  • Genentech USA, Inc.$97K
  • Merck$61K
  • Sanofi$33K
  • plus $36K from 10 others

What the payments were for

  • Consulting fees$20,5823%
  • Speaking & faculty fees$570,44483%
  • Travel & lodging$80,04512%
  • Food & beverage$14,0292%
  • Education$5970%
  • Other$1,6150%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$687,312 in reported general payments places this provider in the 85th percentile of 580 hematology & oncology providers in Illinois.

See all hematology & oncology providers in Illinois

Medicare billing

Part B allowed, 2024
$36,885
Medicare patients
207
Services billed
525

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CalquenceAcalabrutinib Maleate70$936,410
CabometyxCabozantinib S-Malate27$663,807
TasignaNilotinib Hcl27$394,390
XtandiEnzalutamide30$355,698
RevlimidLenalidomide16$284,871
IbrancePalbociclib15$240,670
TazverikTazemetostat Hydrobromide12$183,322
Abiraterone Acetate76$166,487
ErleadaApalutamide14$150,251
SprycelDasatinib20$145,360
VenclextaVenetoclax13$97,778
ImbruvicaIbrutinib14$92,216
XareltoRivaroxaban13$18,697
EliquisApixaban13$18,586
Exemestane19$5,326

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaCalquence$132,756$936,41070 claims
Exelixis Inc.Cabometyx$210,335$663,80727 claims
NovartisTasigna$24,505$394,39027 claims
Astellas Pharma US IncXtandi$30$355,69830 claims
PfizerIbrance, Eliquis$3,389$259,25628 claims
Johnson & JohnsonErleada, Xarelto$165$168,94727 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 580 hematology & oncology providers in Illinois.

Other hematology & oncology in Berwyn

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →